TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) from its SEC filings: 2025 revenue $17.3 billion (+4% vs the year before), net margin 8%, free cash flow $1.6 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $17.3 billion |
| Revenue growth | +4% |
| Net income | $1.4 billion |
| Net margin | 8.2% |
| Free cash flow | $1.6 billion |
| Diluted EPS | $1.21 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -1% |
| Cash | $3.7 billion |
| Long-term debt | $28.8 billion |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.